The global patient engagement solutions market size was USD 19.83 billion in 2023, estimated at USD 22.87 billion in 2024 and is anticipated to reach around USD 89.26 billion by 2034, expanding at a CAGR of 14.59% from 2024 to 2034.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Functionality Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Patient Engagement Solutions Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Patient Engagement Solutions Market, by Delivery Type, 2024-2034
8.1.1. Web-based/Cloud-based
8.1.1.1. Market Revenue and Forecast (2021-2034)
8.1.2. On-premise
8.1.2.1. Market Revenue and Forecast (2021-2034)
9.1. Patient Engagement Solutions Market, by Component Type, 2024-2034
9.1.1. Software
9.1.1.1. Market Revenue and Forecast (2021-2034)
9.1.2. Services
9.1.2.1. Market Revenue and Forecast (2021-2034)
9.1.3. Hardware
9.1.3.1. Market Revenue and Forecast (2021-2034)
10.1. Patient Engagement Solutions Market, by End Use Type, 2024-2034
10.1.1. Payers
10.1.1.1. Market Revenue and Forecast (2021-2034)
10.1.2. Providers
10.1.2.1. Market Revenue and Forecast (2021-2034)
10.1.3. Individual Users
10.1.3.1. Market Revenue and Forecast (2021-2034)
11.1. Patient Engagement Solutions Market, by Application Type, 2024-2034
11.1.1. Social Management
11.1.1.1. Market Revenue and Forecast (2021-2034)
11.1.2. Health Management
11.1.2.1. Market Revenue and Forecast (2021-2034)
11.1.3. Home Healthcare Management
11.1.3.1. Market Revenue and Forecast (2021-2034)
11.1.4. Financial Health Management
11.1.4.1. Market Revenue and Forecast (2021-2034)
12.1. Patient Engagement Solutions Market, by Therapeutic Area, 2024-2034
12.1.1. Chronic Diseases
12.1.1.1. Market Revenue and Forecast (2021-2034)
12.1.2. Fitness
12.1.2.1. Market Revenue and Forecast (2021-2034)
12.1.3. Women’s Health
12.1.3.1. Market Revenue and Forecast (2021-2034)
12.1.4. Mental Health
12.1.4.1. Market Revenue and Forecast (2021-2034)
12.1.5. Others
12.1.5.1. Market Revenue and Forecast (2021-2034)
13.1. Patient Engagement Solutions Market, by Component Type, 2024-2034
13.1.1. Communication
13.1.1.1. Market Revenue and Forecast (2021-2034)
13.1.2. Health Tracking & Insights
13.1.2.1. Market Revenue and Forecast (2021-2034)
13.1.3. Billing & Payments
13.1.3.1. Market Revenue and Forecast (2021-2034)
13.1.4. Administrative
13.1.4.1. Market Revenue and Forecast (2021-2034)
13.1.5. Patient Education
13.1.5.1. Market Revenue and Forecast (2021-2034)
13.1.6. Others
13.1.6.1. Market Revenue and Forecast (2021-2034)
14.1. North America
14.1.1. Market Revenue and Forecast, by Delivery (2021-2034)
14.1.2. Market Revenue and Forecast, by Component (2021-2034)
14.1.3. Market Revenue and Forecast, by End Use (2021-2034)
14.1.4. Market Revenue and Forecast, by Application (2021-2034)
14.1.5. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
14.1.6. Market Revenue and Forecast, by Functionality (2021-2034)
14.1.7. U.S.
14.1.7.1. Market Revenue and Forecast, by Delivery (2021-2034)
14.1.7.2. Market Revenue and Forecast, by Component (2021-2034)
14.1.7.3. Market Revenue and Forecast, by End Use (2021-2034)
14.1.7.4. Market Revenue and Forecast, by Application (2021-2034)
14.1.8. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
14.1.8.1. Market Revenue and Forecast, by Functionality (2021-2034)
14.1.9. Rest of North America
14.1.9.1. Market Revenue and Forecast, by Delivery (2021-2034)
14.1.9.2. Market Revenue and Forecast, by Component (2021-2034)
14.1.9.3. Market Revenue and Forecast, by End Use (2021-2034)
14.1.9.4. Market Revenue and Forecast, by Application (2021-2034)
14.1.10. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
14.1.11. Market Revenue and Forecast, by Functionality (2021-2034)
14.1.11.1.
14.2. Europe
14.2.1. Market Revenue and Forecast, by Delivery (2021-2034)
14.2.2. Market Revenue and Forecast, by Component (2021-2034)
14.2.3. Market Revenue and Forecast, by End Use (2021-2034)
14.2.4. Market Revenue and Forecast, by Application (2021-2034)
14.2.5. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
14.2.6. Market Revenue and Forecast, by Functionality (2021-2034)
14.2.7.
14.2.8. UK
14.2.8.1. Market Revenue and Forecast, by Delivery (2021-2034)
14.2.8.2. Market Revenue and Forecast, by Component (2021-2034)
14.2.8.3. Market Revenue and Forecast, by End Use (2021-2034)
14.2.9. Market Revenue and Forecast, by Application (2021-2034)
14.2.10. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
14.2.10.1. Market Revenue and Forecast, by Functionality (2021-2034)
14.2.11. Germany
14.2.11.1. Market Revenue and Forecast, by Delivery (2021-2034)
14.2.11.2. Market Revenue and Forecast, by Component (2021-2034)
14.2.11.3. Market Revenue and Forecast, by End Use (2021-2034)
14.2.12. Market Revenue and Forecast, by Application (2021-2034)
14.2.13. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
14.2.14. Market Revenue and Forecast, by Functionality (2021-2034)
14.2.14.1.
14.2.15. France
14.2.15.1. Market Revenue and Forecast, by Delivery (2021-2034)
14.2.15.2. Market Revenue and Forecast, by Component (2021-2034)
14.2.15.3. Market Revenue and Forecast, by End Use (2021-2034)
14.2.15.4. Market Revenue and Forecast, by Application (2021-2034)
14.2.16. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
14.2.16.1. Market Revenue and Forecast, by Functionality (2021-2034)
14.2.17. Rest of Europe
14.2.17.1. Market Revenue and Forecast, by Delivery (2021-2034)
14.2.17.2. Market Revenue and Forecast, by Component (2021-2034)
14.2.17.3. Market Revenue and Forecast, by End Use (2021-2034)
14.2.17.4. Market Revenue and Forecast, by Application (2021-2034)
14.2.18. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
14.2.18.1. Market Revenue and Forecast, by Functionality (2021-2034)
14.3. APAC
14.3.1. Market Revenue and Forecast, by Delivery (2021-2034)
14.3.2. Market Revenue and Forecast, by Component (2021-2034)
14.3.3. Market Revenue and Forecast, by End Use (2021-2034)
14.3.4. Market Revenue and Forecast, by Application (2021-2034)
14.3.5. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
14.3.6. Market Revenue and Forecast, by Functionality (2021-2034)
14.3.7. India
14.3.7.1. Market Revenue and Forecast, by Delivery (2021-2034)
14.3.7.2. Market Revenue and Forecast, by Component (2021-2034)
14.3.7.3. Market Revenue and Forecast, by End Use (2021-2034)
14.3.7.4. Market Revenue and Forecast, by Application (2021-2034)
14.3.8. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
14.3.9. Market Revenue and Forecast, by Functionality (2021-2034)
14.3.10. China
14.3.10.1. Market Revenue and Forecast, by Delivery (2021-2034)
14.3.10.2. Market Revenue and Forecast, by Component (2021-2034)
14.3.10.3. Market Revenue and Forecast, by End Use (2021-2034)
14.3.10.4. Market Revenue and Forecast, by Application (2021-2034)
14.3.11. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
14.3.11.1. Market Revenue and Forecast, by Functionality (2021-2034)
14.3.12. Japan
14.3.12.1. Market Revenue and Forecast, by Delivery (2021-2034)
14.3.12.2. Market Revenue and Forecast, by Component (2021-2034)
14.3.12.3. Market Revenue and Forecast, by End Use (2021-2034)
14.3.12.4. Market Revenue and Forecast, by Application (2021-2034)
14.3.12.5. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
14.3.12.6. Market Revenue and Forecast, by Functionality (2021-2034)
14.3.13. Rest of APAC
14.3.13.1. Market Revenue and Forecast, by Delivery (2021-2034)
14.3.13.2. Market Revenue and Forecast, by Component (2021-2034)
14.3.13.3. Market Revenue and Forecast, by End Use (2021-2034)
14.3.13.4. Market Revenue and Forecast, by Application (2021-2034)
14.3.13.5. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
14.3.13.6. Market Revenue and Forecast, by Functionality (2021-2034)
14.4. MEA
14.4.1. Market Revenue and Forecast, by Delivery (2021-2034)
14.4.2. Market Revenue and Forecast, by Component (2021-2034)
14.4.3. Market Revenue and Forecast, by End Use (2021-2034)
14.4.4. Market Revenue and Forecast, by Application (2021-2034)
14.4.5. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
14.4.6. Market Revenue and Forecast, by Functionality (2021-2034)
14.4.7. GCC
14.4.7.1. Market Revenue and Forecast, by Delivery (2021-2034)
14.4.7.2. Market Revenue and Forecast, by Component (2021-2034)
14.4.7.3. Market Revenue and Forecast, by End Use (2021-2034)
14.4.7.4. Market Revenue and Forecast, by Application (2021-2034)
14.4.8. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
14.4.9. Market Revenue and Forecast, by Functionality (2021-2034)
14.4.10. North Africa
14.4.10.1. Market Revenue and Forecast, by Delivery (2021-2034)
14.4.10.2. Market Revenue and Forecast, by Component (2021-2034)
14.4.10.3. Market Revenue and Forecast, by End Use (2021-2034)
14.4.10.4. Market Revenue and Forecast, by Application (2021-2034)
14.4.11. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
14.4.12. Market Revenue and Forecast, by Functionality (2021-2034)
14.4.13. South Africa
14.4.13.1. Market Revenue and Forecast, by Delivery (2021-2034)
14.4.13.2. Market Revenue and Forecast, by Component (2021-2034)
14.4.13.3. Market Revenue and Forecast, by End Use (2021-2034)
14.4.13.4. Market Revenue and Forecast, by Application (2021-2034)
14.4.13.5. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
14.4.13.6. Market Revenue and Forecast, by Functionality (2021-2034)
14.4.14. Rest of MEA
14.4.14.1. Market Revenue and Forecast, by Delivery (2021-2034)
14.4.14.2. Market Revenue and Forecast, by Component (2021-2034)
14.4.14.3. Market Revenue and Forecast, by End Use (2021-2034)
14.4.14.4. Market Revenue and Forecast, by Application (2021-2034)
14.4.14.5. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
14.4.14.6. Market Revenue and Forecast, by Functionality (2021-2034)
14.5. Latin America
14.5.1. Market Revenue and Forecast, by Delivery (2021-2034)
14.5.2. Market Revenue and Forecast, by Component (2021-2034)
14.5.3. Market Revenue and Forecast, by End Use (2021-2034)
14.5.4. Market Revenue and Forecast, by Application (2021-2034)
14.5.5. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
14.5.6. Market Revenue and Forecast, by Functionality (2021-2034)
14.5.7. Brazil
14.5.7.1. Market Revenue and Forecast, by Delivery (2021-2034)
14.5.7.2. Market Revenue and Forecast, by Component (2021-2034)
14.5.7.3. Market Revenue and Forecast, by End Use (2021-2034)
14.5.7.4. Market Revenue and Forecast, by Application (2021-2034)
14.5.8. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
14.5.8.1. Market Revenue and Forecast, by Functionality (2021-2034)
14.5.9. Rest of LATAM
14.5.9.1. Market Revenue and Forecast, by Delivery (2021-2034)
14.5.9.2. Market Revenue and Forecast, by Component (2021-2034)
14.5.9.3. Market Revenue and Forecast, by End Use (2021-2034)
14.5.9.4. Market Revenue and Forecast, by Application (2021-2034)
14.5.9.5. Market Revenue and Forecast, by Therapeutic Area (2021-2034)
14.5.9.6. Market Revenue and Forecast, by Functionality (2021-2034)
15.1. McKesson Corporation
15.1.1. Company Overview
15.1.2. Product Offerings
15.1.3. Financial Performance
15.1.4. Recent Initiatives
15.2. Allscripts Healthcare Solutions
15.2.1. Company Overview
15.2.2. Product Offerings
15.2.3. Financial Performance
15.2.4. Recent Initiatives
15.3. Orion Health Ltd.
15.3.1. Company Overview
15.3.2. Product Offerings
15.3.3. Financial Performance
15.3.4. Recent Initiatives
15.4. GetWellNetwork Inc.
15.4.1. Company Overview
15.4.2. Product Offerings
15.4.3. Financial Performance
15.4.4. Recent Initiatives
15.5. Cerner Corporation
15.5.1. Company Overview
15.5.2. Product Offerings
15.5.3. Financial Performance
15.5.4. Recent Initiatives
15.6. Medecision Inc.
15.6.1. Company Overview
15.6.2. Product Offerings
15.6.3. Financial Performance
15.6.4. Recent Initiatives
15.7. Phytel Inc.
15.7.1. Company Overview
15.7.2. Product Offerings
15.7.3. Financial Performance
15.7.4. Recent Initiatives
15.8. Athenahealth Inc.
15.8.1. Company Overview
15.8.2. Product Offerings
15.8.3. Financial Performance
15.8.4. Recent Initiatives
15.9. YourCareUniverse Inc.
15.9.1. Company Overview
15.9.2. Product Offerings
15.9.3. Financial Performance
15.9.4. Recent Initiatives
15.10. Lincor Solutions Ltd.
15.10.1. Company Overview
15.10.2. Product Offerings
15.10.3. Financial Performance
15.10.4. Recent Initiatives
16.1. Primary Research
16.2. Secondary Research
16.3. Assumptions
17.1. About Us
17.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client